The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1529
September 11, 2017
View Complete Issue         Table of Contents 2019 
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
September 11, 2017 (Issue: 1529)
The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with type 2 diabetes inadequately...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
Article code: 1529a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.